Medicare Is About to Cover Weight-Loss Drugs for $50

A Shift 60 Years in the Making

Starting July 1, 2026, Medicare will offer eligible beneficiaries access
to GLP-1 weight-loss medications for 50 dollars per month - the first
time in Medicare’s six decades that the program has covered drugs
prescribed specifically for obesity. The Centers for Medicare and
Medicaid Services announced the initiative in May 2026, describing it as
a short-term demonstration program called the Medicare GLP-1 Bridge.

The program runs from July 1, 2026, through December 31, 2027. CMS
Administrator Dr. Mehmet Oz said at the announcement that too many
seniors had been unable to access these treatments due to cost, and that
the Bridge was designed to change that.

Which Drugs Are Covered and What They Cost

The Medicare GLP-1 Bridge covers three medications approved for weight
loss: Wegovy in both injection and tablet form, the KwikPen formulation
of Zepbound, and Foundayo in pill form. Eligible beneficiaries pay a
flat copay of 50 dollars per monthly supply, with no deductible applied
through the Bridge program. According to NPR, current retail prices for
these medications - without insurance coverage - typically range from
149 to 699 dollars per month, depending on the drug and dose.

The 50-dollar copay does not count toward the standard Medicare Part D
annual out-of-pocket cap of 2,100 dollars, and it is not reduced by the
Extra Help low-income subsidy. That flat cost applies regardless of
where a beneficiary is in their Part D benefit cycle.

Who Qualifies

To access coverage through the Medicare GLP-1 Bridge, beneficiaries must
be enrolled in a Medicare Part D prescription drug plan or a Medicare
Advantage plan that includes drug coverage. Clinical eligibility is
based on body weight and health status. According to CMS, people qualify
if they have a body mass index of 30 or higher and have at least one
weight-related health condition - such as heart disease, prediabetes,
high blood pressure, or sleep apnea, among others.

A prior authorization from the program is required. Importantly, the
Bridge operates outside of the standard Part D benefit, which means a
beneficiary’s Part D plan does not need to approve the medication
separately. CMS is handling the central processing and payment to
pharmacies directly.

For Those Already Taking a GLP-1

Beneficiaries who were already taking a covered GLP-1 medication before
July 1 may still qualify, as long as their prescriber can attest that
they met the clinical eligibility criteria when they first started the
medication. The BMI requirement is assessed at the time therapy
originally began, not at the time of the Bridge application.

What the Program Is Not

CMS is explicit that the GLP-1 Bridge is a demonstration, not a
permanent Medicare benefit. It runs for 18 months and was designed in
part to generate utilization data ahead of a longer-term program - known
as BALANCE - that was originally set to begin in January 2027. CMS
announced in May 2026 that the BALANCE program’s Part D component would
be delayed indefinitely, meaning the Bridge now stands as the primary
access pathway through the end of 2027.

The program also covers only medications prescribed for weight loss.
GLP-1 drugs prescribed for diabetes management, cardiovascular disease,
or sleep apnea are handled through standard Part D coverage and are not
part of the Bridge.

A Practical Step Before July 1

Medicare beneficiaries who believe they may be eligible can check their
eligibility and learn more at Medicare.gov/glp1bridge or by calling
1-800-MEDICARE. The prior authorization process officially opens on July
1, 2026. Beneficiaries already on a GLP-1 for weight loss should ask
their prescriber to confirm that relevant medical records from when the
treatment started are available and on file ahead of the program launch.

For many older Americans who have been managing weight-related health
conditions while watching the cost of these medications remain out of
reach, July 1 represents a meaningful and concrete change to what their
coverage can actually do.

References: CMS: $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries | A new Medicare option for weight loss drugs is coming